Scinopharm Taiwan, Ltd.

Yuan-Chang Huang

Tsung-Cheng Hu

Wen-Wei Lin

Yuan-Xiu Liao

Yung-Hung Chang

Kuan-Hsun Wang

Crystalline form S1 of irinotecan free base characterized by a powder X-ray diffraction pattern with peaks at about 8.7&#xb1;0.2, 13.1&#xb1;0.2, 14.5&#xb1;0.2, 17.4&#xb1;0.2, 18.4&#xb1;0.2, 20.9&#xb1;0.2, 24.0&#xb1;0.2 and 27.5&#xb1;0.2 degrees two-theta degrees two-theta, and crystalline form S2 of irinotecan free base characterized by a powder X-ray diffraction pattern with peaks at about 7.1&#xb1;0.2, 10.6&#xb1;0.2, 12.4&#xb1;0.2, 20.6&#xb1;0.2, 21.6&#xb1;0.2 and 24.2&#xb1;0.2 degrees two-theta.

Polymorphism for irinotecan free base

In certain aspects, the invention provides a novel crystalline form of olaparib (4-[(3-[(4-cyclopropylcarbonyl)piperazin-4-yl]carbonyl)-4-fluorophenyl]methyl(2H)phthalazin-1-one). In related aspects, the invention provides a processe for preparing the novel crystalline form of olaparib. The process includes forming a solution comprising crude olaparib and an organic solvent; adding the solution to an anti-solvent to form a slurry comprising a precipitate; isolating the precipitate; and drying the precipitate to obtain a crystalline form III of olaparib.

Crystalline form of olaparib and a process for preparing the same

In certain aspects, the invention provides crystalline forms of olaparib (4-[(3-[(4-cyclopropylcarbonyl)piperazin-4-yl]carbonyl)-4-fluorophenyl]methyl(2H)phthalazin-1-one). In related aspects, the invention provides processes for preparing the crystalline forms of olaparib. The processes include: forming a solution comprising crude olaparib and an organic solvent; adding an anti-solvent to the solution to form a slurry comprising a precipitate; isolating the precipitate; and drying the precipitate to obtain a crystalline form I of olaparib or a crystalline form II of olaparib.

Growing community of inventors

Tainan, Taiwan

Yuan-Chang Huang